To evaluate the effects of transcutaneous electrical nerve stimulation (TENS) on bladder management, pelvic floor muscle strength, and quality of life (QoL) in patients undergoing nerve-sparing radical hysterectomy (NSRH) for cervical cancer. A total of 78 NSRH patients during May 2023-May 2024 were divided into conventional catheter management (control group, n = 39) and conventional management + TENS (intervention group, n = 39). Outcomes including urinary retention incidence, postvoid residual urine volume (PVR), catheter indwelling duration, intervention compliance, pelvic floor muscle strength grading, voiding function parameters \[first desire to void (FD), bladder compliance (BC), maximum cystometric capacity (MCC)\], QoL scores (EORTC QLQ-C30: functional, symptom, and global health domains), and safety were assessed. The intervention group demonstrated significantly lower urinary retention incidence, reduced PVR, and shorter catheter duration versus controls (all P \< 0.05). Both groups maintained \> 90% intervention compliance (P \> 0.05). Post-intervention voiding parameters (FD, BC, MCC) improved more significantly in the intervention group (all P \< 0.05), with superior pelvic floor muscle strength grading (P \< 0.001). QoL assessment revealed lower functional domain scores and higher symptom/global health scores in the intervention group (all P \< 0.001). Safety analysis showed only mild dermal reactions in the intervention group, without significant between-group difference in complication rates (P \> 0.05). TENS significantly improves bladder function, pelvic floor muscle strength, and QoL in post-NSRH patients with a favorable safety profile, demonstrating substantial clinical value.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
78
Low-frequency electrical stimulation (800Hz) applied at CV2/S3 regions twice daily for 7 days using MMK520i device
Fudan University Shanghai Cancer Center
Shanghai, China
Incidence of urinary retention after catheter removal
Proportion of patients with postvoid residual urine volume (PVR) \>100 mL following initial catheter removal, assessed via bladder ultrasound.
Time frame: Within 7 days post-catheter removal (typically postoperative days 14-21).
Postvoid residual urine volume (PVR)
Quantification of residual urine volume (mL) via bladder ultrasound after voiding.
Time frame: Measured immediately after catheter removal and at 1-month follow-up.
Catheter indwelling duration
Total days from surgery to permanent catheter removal.
Time frame: Up to 30 days postoperatively.
Pelvic floor muscle strength grading
Assessed via vaginal examination using a 6-point scale (Grades 0-V).
Time frame: At 1-month post-intervention.
Voiding function parameters (FD, BC, MCC)
* First desire to void (FD): Volume (mL) at initial urge. * Bladder compliance (BC): Δvolume/Δpressure (mL/cmH₂O). * Maximum cystometric capacity (MCC): Volume (mL) at strong urge.
Time frame: Pre-intervention and 1-month post-intervention.
Quality of Life (EORTC QLQ-C30 scores)
Standardized scores for functional, symptom, and global health domains.
Time frame: Pre-intervention and 1-month post-intervention.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.